Share This Page
Drugs in ATC Class H
✉ Email this page to a colleague
Subclasses in ATC: H - Systemic hormonal preparations, excluding sex hormones and insulins
ATC Class H systemic hormonal preparations (excluding sex hormones and insulins): market dynamics and patent landscape
Executive summary
ATC Class H systemic hormonal preparations (excluding sex hormones and insulins) spans a set of distinct drug clusters with different regulatory and IP mechanics: pituitary hormones and analogs (e.g., somatostatin analogs, gonadotropin-releasing hormone variants where classified outside “sex hormones”), corticosteroids, and calcitonin/osteoporosis endocrine agents, plus other systemic endocrine hormones. Market structure is dominated by long-established originators with layered patent estates (compound, formulation, device/dosing, and method-of-use), while competitive entry is increasingly driven by (1) biosimilar-like pathways for complex peptide hormones where available, (2) “thin” reformulation and manufacturing process claims in later patent generations, and (3) patent challenge strategies focused on Orange Book expiry timing and secondary patents.
A complete, accurate ATC-class-wide patent landscape requires drug-by-drug Orange Book and relevant jurisdiction datasets (US Orange Book listings, EPO family data, SPC status, and current litigation). That dataset is not present in the prompt, and a class-wide synthesis without naming the underlying marketed products and their listed patent numbers would not meet accuracy requirements.
Which therapies fall under ATC H systemic hormonal preparations excluding sex hormones and insulins
Featured snippet answer: ATC Class H systemic hormonal preparations covers multiple endocrine subclasses; when excluding sex hormones and insulins, the remaining universe typically concentrates on pituitary hormones/analogues, corticosteroids (oral systemic), thyroid-related hormones, and calcitonin-related agents, plus select endocrine-targeting peptides depending on ATC labeling.
What are the main therapeutic clusters inside “H” once sex hormones and insulin are removed?
Common clusters include:
- Pituitary hormones and analogs
Somatostatin analogs (acromegaly), growth hormone axis agents (where applicable by ATC categorization). - Corticosteroids for systemic use
Oral and systemic formulations (prednisone, dexamethasone, methylprednisolone) are typically off-patent globally, but branded, extended-release, or high-concentration formulations can carry secondary patents. - Calcitonin and related osteopathy endocrine products
Often peptide-based, with formulation IP and device IP (nasal/injectables) shaping exclusivity. - Other systemic endocrine hormones outside “sex hormones” and “insulins”
Specific inclusion depends on ATC subcategory assignments.
Why the patent landscape varies by cluster
- Peptide hormones: higher likelihood of process/formulation claims and device-dosing IP.
- Steroids: compound IP is usually expired; secondary IP often targets specific dosing regimens, crystal forms, and formulation technologies.
- Thyroid and other small molecules: typically constrained to method-of-use and specific salt/strength/formulation claims.
What patents protect systemic hormonal preparations in ATC H (excluding sex hormones and insulin)
Featured snippet answer: Protection typically layers into: (1) core active ingredient claims, (2) polymorph/crystal/solid-state form claims for peptides or salts, (3) formulation claims (stabilizers, buffers, excipients, particle size, lyophilization and reconstitution), (4) device and delivery method claims for injectable and nasal systems, and (5) method-of-use claims tied to specific indications or dosing schedules.
How patent claim types map to real-world exclusivity
- Compound/analog patents
Cover the hormone, analog, or derivative (often expiring first among the estate). - Solid-state and salt/form claims
Common for oral endocrine hormones and certain endocrine small molecules. - Formulation and concentration claims
Capture excipient ratios, stabilization, buffering and pH ranges, reconstitution steps, and storage conditions. - Dosing regimens and treatment protocols
Method-of-use patents for specific patient populations or titration schedules. - Manufacturing-process claims
Particularly relevant for peptide hormones and complex biologics-like products. - Combination product claims (if present)
Less common in “pure” ATC H categories but can arise for endocrine regimens.
Which assignee types dominate
- Originator pharma and biopharma hold primary and late-stage formulation/device patents.
- Specialty generics and biosimilar developers acquire manufacturing-process patents or file around by changing the manufacturing route or formulation.
When does exclusivity end for ATC H drugs, and what dates matter (US FDA exclusivity vs patents)
Featured snippet answer: Commercial exclusivity is driven by the later of (1) patent expiration in the Orange Book and (2) statutory/regulatory exclusivity such as pediatric exclusivity, 5-year new chemical entity (NCE) or new molecular entity (NME) exclusivity, 7-year biologic exclusivity (where applicable), and orphan drug exclusivity, plus any pediatric PRF-related extensions. The practical entry trigger is “last-to-expire” among listed patents and exclusivity.
Patent expiry mechanics that control generic or follow-on entry
- Core patents: often earliest in the estate.
- Secondary patents: formulation, dosing, and method-of-use patents often extend practical market protection.
- Orphan/pediatric extensions: can move the effective entry date.
- Court-triggered stays: can delay entry after a Paragraph IV notice.
What to model for pipeline and launch timing
For each marketed endocrine product in ATC H (excluding sex hormones/insulin), the entry model must track:
- Orange Book listing(s) and their statutory expiration dates
- Any relevant exclusivity types and end dates
- If there is a Paragraph IV filing, the 30-month stay window and litigation outcome
A class-wide “timeline” cannot be accurately stated without enumerating the specific products and their Orange Book patent numbers.
What patent litigation affects systemic hormonal preparations in ATC H
Featured snippet answer: Litigation in ATC H typically targets secondary patents: formulation, method-of-use, and device-related claims, with challenges often filed via Paragraph IV (US) to expedite generic entry. For peptide-like products or complex injectable regimens, litigation frequently centers on process and formulation equivalence and infringement under doctrine-based claim constructions.
Common litigation patterns in endocrine hormones
- Paragraph IV challenges to Orange Book-listed formulation or method-of-use patents.
- Settlement agreements that tie generic entry to specific launch dates or “carve-outs” (limited dosage strengths or indications).
- Injunction appeals that alter the timing but not the ultimate expiry-based trigger.
What matters for investors and licensing teams
- Whether the challenged patents are central (core claim) or peripheral (secondary claim).
- Whether the case includes a § 271(e)(2) “use” or “manufacture” infringement theory aligned to the proposed label and manufacturing route.
A precise litigation map requires the underlying product list and docket-level data.
Which generic entry risks exist for ATC H hormonal preparations
Featured snippet answer: Entry risk is highest where (1) Orange Book estates contain later secondary patents with weak factual infringement positions, (2) product labels are narrow enough that method-of-use claims are harder to infringe, or (3) reformulation changes the formulation-dependent infringement elements. Entry risk is lower where (1) multiple unexpired patents cover the core hormone and key formulations, or (2) prior challengers already settled with broad scope.
How to assess risk by drug category
- Steroid systemic or older endocrine small molecules: most risk already priced in; remaining opportunities cluster in higher-strength, novel delivery, or line extensions.
- Peptide injectables: higher risk for generics where the only barriers are formulation details that can be redesigned; lower risk where device/dosing and method-of-use patents are tightly coupled to the proposed label.
- Nasal or device-led endocrine products: device and formulation patents can raise engineering/IP barriers.
What is the Orange Book status of ATC H systemic hormonal preparations
Featured snippet answer: Orange Book status is product-specific; the class-level answer is that protection is typically present via multiple patent listings per product, with timing dominated by the “last expiring” patent and any exclusivity extensions.
Why a class summary cannot replace a product listing
Orange Book status includes:
- Patent numbers and their claim types
- Expiration dates and whether they are listed as method-of-use or drug substance/product
- Whether exclusivity is tied to NCE/NME/biologic/orphan/pediatric mechanisms
Without enumerating the specific ATC H drugs and their Orange Book records, any assertion would be incomplete.
How does the patent estate for ATC H compare across endocrine clusters
Featured snippet answer: Compared with steroids and older small-molecule endocrine drugs, peptide and device/dosing-sensitive hormonal preparations usually have deeper, more layered patent estates concentrated in formulation, manufacturing, and use/dosing claims.
Relative estate characteristics
- Small molecules (steroids, thyroid-related agents)
Typically fewer “fresh” composition claims, more line-extension and method-of-use remnants. - Peptide hormones
More frequent solid-state/formulation/manufacturing patent density and device dependencies. - Combination regimens (if applicable)
Additional formulation and method-of-use patents can extend exclusivity.
What commercial dynamics drive uptake in ATC H once generic competition appears
Featured snippet answer: In systemic endocrine classes, competitive uptake depends on (1) label equivalence and switching interchangeability, (2) patient handling characteristics (injectable stability, reconstitution, nasal device performance), (3) payer dynamics (step edits, prior auth, tendering), and (4) pricing pressure that accelerates once key secondary patents expire or are designed around.
Observed market levers
- Form factor and stability: can slow substitution even after active ingredient parity.
- Dosing regimen match: method-of-use and regimen differences affect prescribing behavior.
- Reimbursement constraints: payer rules can delay effective switching.
A quantified market-share response requires product-level revenue, payer policies, and launch timing data.
Key takeaways
- ATC Class H (excluding sex hormones and insulins) is not a single patent regime. It is a set of endocrine clusters with distinct claim patterns.
- Enduring protection is commonly driven by layered secondary patents (formulation, solid state, dosing/method-of-use, device).
- Generic risk and entry timing are product-specific and depend on Orange Book “last expiring” patents plus exclusivity and any Paragraph IV litigation and settlements.
- A complete patent landscape must start from a defined list of ATC H marketed products and their Orange Book listings, then map each product’s estate and legal status.
FAQs
- How do secondary formulation patents most often extend protection for systemic endocrine injectables in ATC H?
- What label elements (indication, dosing, administration) determine whether method-of-use claims are likely to be infringed in ATC H generic filings?
- When do pediatric exclusivity extensions materially change the generic entry date for endocrine hormonal products?
- How do settlement agreements in Paragraph IV cases typically structure “carve-out” launches for endocrine drugs?
- What manufacturing-process differences can mitigate infringement risk for peptide-like systemic hormones with layered formulation patents?
References (APA)
- U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-06-05).
More… ↓
